Expert Review of Endocrinology & Metabolism is a premier journal dedicated to advancing the field of endocrinology and metabolism, published by Routledge Journals, Taylor & Francis Ltd, in the United Kingdom. With a robust focus on the latest research, innovative treatments, and clinical practices, this journal serves as an essential resource for healthcare professionals, researchers, and students seeking to stay abreast of developments in diabetes, obesity, thyroid disorders, and other endocrine-related conditions. Achieving a commendable Q2 status in Endocrinology, Diabetes, and Metabolism in the 2023 ranking, Expert Review of Endocrinology & Metabolism holds strong standing with an impressive Scopus rank, placing it at the 53rd percentile among its peers. The journal embraces a comprehensive approach, offering critical reviews, original research articles, and insights on emerging trends and technologies in the field. Although not an open-access journal, it provides extensive access options for subscribers and institutions, encouraging ease of dissemination and academic engagement. Through its commitment to high-quality content, Expert Review of Endocrinology & Metabolism remains pivotal for professionals aiming to enhance their understanding and practice in this vital area of medicine.

Diabetes Stoffwechsel und Herz, published by VERLAG KIRCHHEIM, is a distinguished journal that focuses on the interdisciplinary field of diabetes research, cardiology, and metabolic disorders. With its dedicated approach, the journal aims to disseminate cutting-edge findings and foster innovative discussions among researchers and practitioners in the healthcare community. Despite its discontinuation in Scopus coverage since 2017, the journal continues to hold significance in advancing knowledge regarding the intricate relationship between diabetes and cardiovascular health. It offers researchers a platform to explore the biochemical, genetic, and clinical aspects of endocrinology, while also catering to the needs of professionals aiming to apply the latest research in their practice. The journal’s rankings, which place it in the lower percentiles across various relevant categories, reflect a unique opportunity for contributors looking to impact a niche yet vital area of medicine. As the field evolves, Diabetes Stoffwechsel und Herz remains committed to enriching the dialogue surrounding these critical health issues.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.

HORMONE AND METABOLIC RESEARCH, published by GEORG THIEME VERLAG KG, stands as a reputable platform in the fields of biochemistry, endocrinology, and metabolism since its establishment in 1969. This peer-reviewed journal provides critical insights and advancements in the intricate relationships between hormones and metabolic processes, catering to researchers, healthcare professionals, and students alike. With an impressive convergence of knowledge spanning over five decades, it maintains a commendable Q3 ranking in multiple categories, including Biochemistry, Clinical Biochemistry, and Endocrinology, highlighting its contribution to cutting-edge scientific discourse. Although not an open-access journal, it offers a plethora of access options for readers and institutions, ensuring that vital research reaches those who need it most. Located in Stuttgart, Germany, the journal is positioned at the forefront of influential research in hormone and metabolic studies, emphasizing its importance for ongoing investigations into health and disease.

Journal of Endocrinology and Metabolism is a dynamic and essential publication in the field of endocrinology, diabetes, and metabolism, published by ELMER PRESS INC in Canada. With an ISSN of 1923-2861 and E-ISSN 1923-287X, this journal serves as a pivotal platform for sharing innovative research and advancements from 2018 through 2024. Although categorized in the fourth quartile (Q4) for 2023, its commitment to high-quality research is reflected in its ongoing efforts to foster scholarly dialogue and illuminate critical issues within its scope. Targeting primarily researchers, healthcare professionals, and students, the journal aims to disseminate crucial findings that advance our understanding of endocrine functions and metabolic processes. Given its Scopus ranking of #207 out of 244 within its category, the Journal of Endocrinology and Metabolism continues to contribute to the global discourse on these vital health topics.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

Journal of Endocrinology Metabolism and Diabetes of South Africa, published by Routledge Journals, Taylor & Francis Ltd, serves as a vital platform for advancing research and knowledge dissemination in the fields of endocrinology, metabolism, and diabetes. Since its transition to Open Access in 2012, it has enabled greater accessibility to crucial findings and data, broadening its reach to researchers, practitioners, and students alike. Though its coverage in Scopus was discontinued in 2018, the journal continues to play an important role in fostering discourse in the medical community, as evidenced by its ranking within the 19th and 16th percentiles for Internal Medicine and Endocrinology, diabetes and metabolism, respectively. With its commitment to addressing pressing health issues in South Africa and beyond, this journal remains an invaluable resource for those seeking to understand and tackle the complexities of metabolic diseases.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Welcome to the Journal of the ASEAN Federation of Endocrine Societies, a pioneering publication dedicated to advancing knowledge and research in the fields of Endocrinology, Diabetes, and Metabolism. Established by the ASEAN Federation Endocrine Society and open access since 2011, this journal enhances the dissemination of critical findings and encourages collaboration among professionals and researchers across Southeast Asia and beyond. With an ISSN of 0857-1074 and E-ISSN of 2308-118X, the journal is indexed within Quartile 4 in the 2023 rankings of its categories, reflecting its commitment to providing a platform for scholarly work despite its emerging status. Situated in the Philippines, the journal focuses on the latest trends, treatments, and innovative research approaches in endocrinology, making it an essential resource for academics, clinicians, and students alike. We invite you to explore our content and contribute to advancing the endocrine sciences.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.